Meningococcal A, C, W-135, and Y capsular polysaccharide-specific B-cell receptor (MenACWY-specific BCR)

Meningococcal A, C, W-135, and Y capsular polysaccharide-specific B-cell receptors are membrane-bound immunoglobulins expressed on the surface of B lymphocytes (UniProt, 2024). These receptors are specialized to recognize and bind to the unique repeating carbohydrate epitopes of the capsular polysaccharides from Neisseria meningitidis serogroups A, C, W-135, and Y (Pollard et al., 2009). Upon binding to their cognate antigens—typically delivered via conjugate vaccines like Menveo or Menactra—these receptors trigger intracellular signaling pathways that drive B-cell activation and differentiation (CDC, 2023). This process is essential for the production of bactericidal antibodies, which provide protection against invasive meningococcal disease (Goldschneider et al., 1969). The engagement of these receptors on naïve B cells leads to the formation of memory B cells, ensuring long-term immunity (Borrow et al., 2013). These receptors are the primary biological targets for quadrivalent meningococcal vaccines, which aim to elicit a robust and durable immune response to prevent life-threatening meningitis and septicemia (WHO, 2023). In the context of conjugate vaccines, the BCR recognizes the polysaccharide while the carrier protein provides T-cell help, enhancing the affinity maturation of these receptors (Pace et al., 2009). Monitoring the frequency and affinity of these receptors is a key component of evaluating vaccine efficacy in clinical trials (Findlow et al., 2014).

Other names

MenACWY-specific B-cell receptorNeisseria meningitidis capsular polysaccharide-specific BCRAnti-meningococcal polysaccharide B-cell receptorMeningococcal A/C/W-135/Y polysaccharide-specific B-cell receptor

Vaccine antigens (capsular polysaccharides or glycoconjugates) bind to these specific B-cell receptors, initiating signal transduction that leads to B-cell proliferation, differentiation into antibody-secreting plasma cells, and the generation of long-lived memory B cells (CDC, 2023).